generation run 2026-05-09
9,024 min completedmodel pipeline-v5plan not recordedrun/65e4bbce…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_protocol_abbreviated
- no_standardized_schedule
- withdrawal_severity
Reproduce
- inputs
- 36 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
28 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | ClinicalTrials.gov | gamma-hydroxybutyrate sodium oxybate GHB treatment | 10 | 3 | Relevant clinical context for GBL-as-GHB-prodrug |
| 2 | ClinicalTrials.gov · absence | gamma-butyrolactone GBL | 0 | — | GBL has no direct clinical trial registrations |
| 3 | OpenAlex | GHB GBL gamma-hydroxybutyrate abuse dependence withdrawal treatment | 10 | 4 | Important mechanistic and clinical reviews |
| 4 | PubMed | GBL gamma-butyrolactone abuse dependence withdrawal syndrome | 12 | 9 | Key papers on GBL dependence, withdrawal, case reports |
| 5 | PubMed | gamma-hydroxybutyrate GABA-B receptor binding affinity pharmacodynamics | 10 | 5 | Core receptor pharmacology papers |
| 6 | PubMed | GHB sodium oxybate pharmacokinetics bioavailability half-life human | 1 | 1 | Human PK data |
| 7 | PubMed | gamma-butyrolactone chemsex recreational use prevalence epidemiology | 9 | 2 | — |
| 8 | PubMed | GBL GHB conversion metabolism pharmacokinetics | 2 | 2 | Core toxicology review and forensic case series |
| 9 | OpenAlex | gamma-butyrolactone GHB pharmacology GABA receptor | 10 | 5 | — |
| 10 | PubChem | gamma-butyrolactone | 1 | 1 | Verified chemical identity data for GBL |
| 11 | PubMed | gamma-butyrolactone GBL pharmacology mechanism action | 12 | 2 | — |
| 12 | WebSearch | GBL gamma-butyrolactone UK Misuse of Drugs Act 2009 Schedule Australia legal | 10 | 2 | — |
| 13 | PubMed | PMID 18523892 MCT transport GHB | 1 | 1 | — |
| 14 | PMC | First UK fatality GBL ingestion PMC2789020 | 1 | 1 | — |
| 15 | PubMed | GHB GBL acute intoxication coma bradycardia respiratory emergency management | 3 | 3 | — |
| 16 | OpenAlex | gamma-butyrolactone GBL harm reduction risk dose subjective effects users | 10 | 3 | — |
| 17 | PubMed | GBL GHB drug facilitated sexual assault DFSA forensic | 5 | 4 | — |
| 18 | ClinicalTrials.gov | gamma-hydroxybutyrate sodium oxybate GHB treatment | 10 | 3 | — |
| 19 | WebSearch | GBL gamma-butyrolactone legal status scheduling UK USA Australia Europe | 10 | 3 | — |
| 20 | PubMed | PMID 37343712 | 1 | — | — |
| 21 | NCBI Bookshelf / IARC | gamma-butyrolactone chemical properties toxicology NBK498936 | 1 | 2 | — |
| 22 | PubMed | PMID 26855327 | 1 | — | — |
| 23 | WebSearch | Henri Laborit GHB gamma-hydroxybutyrate first synthesis 1960 1961 GABA analog history | 10 | 2 | — |
| 24 | WebSearch | GBL gamma-butyrolactone history industrial use solvent CAS 96-48-0 SMILES chemical properties | 10 | 2 | — |
| 25 | Crossref/DOI verification | 10.3109/15563650.2012.702218 and 10.2174/1570159X13666141210215423 | 2 | 2 | — |
| 26 | PubMed | PMID 26242455, 21073808 | 2 | 2 | — |
| 27 | PubMed | GHB GBL acute intoxication clinical features emergency department ED presentations | 3 | 3 | — |
| 28 | Compiled from all sources | GBL chemical identity, pharmacology, toxicology, legal status, history synthesis | 48 | 2 | — |
127 claims by section — every cited sentence, checked against its source
safety43 · 18 ok
GBL produces dose-dependent CNS and respiratory depression that can be fatalsupported
GHB and analogs as CNS depressants. GABA-B agonism mechanism of toxicity. 15563650.2012.702218
Claim in safety — inconclusiveinconclusiveworking →
Plasma ghb concentration thresholds provide a pharmacological framework: ~100 mg/L produces euphoria and disinhibition; ~500 mg/L produces potentially fatal cardiorespiratory depressionsupported
~100 mg/L euphoria, 500 mg/L potentially fatal. 1570159x13666141210215423
The first confirmed UK fatality involved a 25-year-old male with 282 mg/L GBL in femoral blood; the cause of death was aspiration secondary to GBL-induced comasupported
25yo man found unconscious. Femoral blood GBL: 282 mg/L. Pulmonary aspiration postmortem. First confirmed isolated GBL fatality in UK. jrsm.2009.090283
Lenz et al. (2008) reported two additional GBL fatalities — one suicide, one accidental — with full organ distribution of GHB confirmed by GC/MS.supported
Two GBL fatalities and one nonfatal intoxication. GHB quantified by GC/MS. One suicide, one accidental. ftd.0b013e3181898c2e
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
GBL's role in drug-facilitated sexual assault is well-documented: the compound is colorless, nearly odorless, and produces rapid sedation with amnesia, making covert administration difficult to detect.supported
Reviews chemistry and pharmacology of GHB, GBL, and 1,4-BD and their use in DFSA. pmid:26242455
The short duration (1–2 hours) combined with rapid onset creates a reinforcement cycle in which users redose frequently — in one case report, every 30 minutessupported
24yo man with known GBL abuse (2 mL every 30 min). s-0029-1220252
Claim in safety — inconclusiveinconclusiveworking →
Kashyap and Patel (2011) described a bizarre psychiatric presentation during GBL withdrawal with recovery not occurring until day 11supported
29yo GBL user with bizarre psychiatric presentation. Dramatic recovery day 11. pmid:21894099
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
tolerance to GBL/GHB effects develops rapidly, within several days of regular use. Cross-tolerance exists between GBL, GHB, and 1,4-butanediolsupported
Equimolar doses of GHB, 1,4-BD, and GBL all produce catalepsy. Chronic GHB shows greater tolerance development than GBL or 1,4-BD. j.fct.2012.10.009
Claim in safety — inconclusiveinconclusiveworking →
The neurobiological basis involves adaptations across gaba, glutamate, dopamine, serotonin, norepinephrine, and cholinergic systems, as well as changes in neurosteroidogenesis.supported
Chronic GHB affects GABA, glutamate, dopamine, serotonin, norepinephrine, cholinergic systems. Also neurosteroidogenesis and oxytocin. 000443173
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Benzodiazepines are first-line but provide incomplete efficacy, likely because GHB's primary targets (gaba-b-receptor and extrasynaptic gaba-a-receptor alpha-4/delta) are not addressed by benzodiazepines. phenobarbital and other barbiturates are alternatives, with the rationale that barbiturates activate the same alpha-4/delta GABA-A receptors engaged by GHB. baclofen (GABA-B agonist) is a promising adjunct; a feasibility RCT has been conductedsupported
Resistance to benzodiazepines noted. Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. Barbiturates suggested as alternative. 01.pra.0000452567.84825.07
Benzodiazepines are first-line but provide incomplete efficacy, likely because GHB's primary targets (gaba-b-receptor and extrasynaptic gaba-a-receptor alpha-4/delta) are not addressed by benzodiazepines. phenobarbital and other barbiturates are alternatives, with the rationale that barbiturates activate the same alpha-4/delta GABA-A receptors engaged by GHB. baclofen (GABA-B agonist) is a promising adjunct; a feasibility RCT has been conductedsupported
Resistance to benzodiazepines noted. Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. Barbiturates suggested as alternative. 01.pra.0000452567.84825.07
Benzodiazepines are first-line but provide incomplete efficacy, likely because GHB's primary targets (gaba-b-receptor and extrasynaptic gaba-a-receptor alpha-4/delta) are not addressed by benzodiazepines. phenobarbital and other barbiturates are alternatives, with the rationale that barbiturates activate the same alpha-4/delta GABA-A receptors engaged by GHB. baclofen (GABA-B agonist) is a promising adjunct; a feasibility RCT has been conductedsupported
Benzodiazepines are currently prescribed for detoxification. GABA-B agonist baclofen has shown promise as adjunct. pmid:27677382
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A notable discrepancy exists between animal and human data: standard animal models do not replicate GBL dependence or withdrawal, whereas human clinical evidence consistently demonstrates high dependence potentialsupported
Notes GBL not associated with dependence in animal studies but human case reports show high dependence potential. pmid:21894099
Claim in safety — inconclusiveinconclusiveworking →
Galicia et al. (2019) demonstrated that ethanol co-ingestion significantly worsens clinical outcomes in GHB/GBL intoxication presentationssupported
Ethanol coingestion with GHB/GBL increases sedative effects and worsens clinical outcomes at ED presentations. j.toxlet.2019.07.001
Thai et al. (2006) characterized the GHB-ethanol interaction in humans, confirming synergistic CNS and respiratory depressionsupported
Examines individual and combined effects of GHB and ethanol in human volunteers. GHB can produce serious toxicity particularly when combined with other sedatives. pmid:16974199
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
However, baclofen is also used therapeutically for GBL withdrawal management under medical supervisionsupported
GABA-B agonist baclofen has shown promise as adjunct. pmid:27677382
This pattern is frequently observed in chemsex contextssupported
Reviews GHB/GBL/1,4-BD, mephedrone, methamphetamine and other chemsex drugs. Covers patterns of use. 1570159x15666161117151148
Concurrent alcohol use — synergistic CNS and respiratory depression; lethal combinationsupported
Ethanol coingestion with GHB/GBL increases sedative effects and worsens clinical outcomes at ED presentations. j.toxlet.2019.07.001
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
pharmacology26 · 19 ok
After ingestion, it is hydrolyzed to ghb by blood and tissue lactonases with a conversion half-life of approximately one minutesupported
GBL/BD rapidly converted to GHB (t1/2 ~1 min). 1570159x13666141210215423
Claim in pharmacology — inconclusiveinconclusiveworking →
This was demonstrated conclusively in gaba-b-receptor(1)-knockout mice, in which GBL administration produced no pharmacological effects — no sedation, no catalepsy, no EEG changes — despite intact high-affinity GHB binding sites.supported
GABA-B(1)-/- mice retain GHB-specific binding sites but lose GHB pharmacological effects (hypolocomotion, hypothermia, dopamine synthesis changes, EEG delta waves). All studied GHB effects are GABA-B dependent. pmid:14656321
This was demonstrated conclusively in gaba-b-receptor(1)-knockout mice, in which GBL administration produced no pharmacological effects — no sedation, no catalepsy, no EEG changes — despite intact high-affinity GHB binding sites.supported
GBL and baclofen both require GABA-B receptors for their sedative effects (absent in GABA-B knockout mice). GBL effects fully GABA-B mediated. jneurosci.3145-10.2010
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
GABA-B activation mediates the defining pharmacological effects: sedation, hypothermia, catalepsy, hypolocomotion, and characteristic EEG delta-wave inductionsupported
GABA-B(1)-/- mice lose GHB pharmacological effects (hypolocomotion, hypothermia, dopamine synthesis changes, EEG delta waves). All studied GHB effects are GABA-B dependent. pmid:14656321
GABA-B activation mediates the defining pharmacological effects: sedation, hypothermia, catalepsy, hypolocomotion, and characteristic EEG delta-wave inductionsupported
GBL and baclofen both require GABA-B receptors for their sedative effects (absent in GABA-B knockout mice). GBL effects fully GABA-B mediated. jneurosci.3145-10.2010
The GBL/GHB-induced EEG pattern is distinct from physiological sleep and differs from baclofen-induced effects despite shared GABA-B agonism, suggesting subtype-selective or kinetically distinct receptor engagement.supported
GBL induces drug-distinct-from-physiological-sleep state, not associated with subsequent hypersomnia unlike baclofen. jneurosci.3145-10.2010
Wellendorph et al. (2025) identified these sites as the alpha subunit of Ca²⁺/calmodulin-dependent protein kinase II (CaMKII-alpha), a kinase central to neuroplasticity and long-term potentiationsupported
Comprehensive IUPHAR review identifying CaM-dependent protein kinase II alpha subunit as high-affinity GHB target. j.pharmr.2025.100064
This discovery positions GHB as an integrator of inhibitory (GABA-B) and excitatory (CaMKII) signaling — a dual mechanism that may underlie the compound's complex dose-dependent behavioral profile.supported
GHB weak agonist at GABA-B; high-affinity binding at CaMKII-alpha subunit. j.pharmr.2025.100064
Claim in pharmacology — not_supportednot supportedworking →
Extrasynaptic GABA-A receptors (alpha-4/delta subunits). GHB activates extrasynaptic GABA-A receptors containing alpha-4 and delta subunits — a receptor population that is insensitive to benzodiazepines but strongly activated by barbituratessupported
Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. Barbiturates suggested as alternative. 01.pra.0000452567.84825.07
Claim in pharmacology — inconclusiveinconclusiveworking →
Chronic GHB/GBL exposure produces neuroadaptations across multiple neurotransmitter systems — gaba, glutamate, dopamine, serotonin, norepinephrine, and cholinergic pathways — as well as alterations in neurosteroidogenesis and oxytocin release.supported
Chronic GHB affects GABA, glutamate, dopamine, serotonin, norepinephrine, cholinergic systems. Also neurosteroidogenesis and oxytocin. 000443173
Following oral GBL ingestion, plasma GHB reaches maximum concentration (Cmax) at 20–60 minutespartially supported
Cmax 20-40 min. 1570159x13666141210215423
Following oral GBL ingestion, plasma GHB reaches maximum concentration (Cmax) at 20–60 minutespartially supported
Absorption time 5-45 min. j.yrtph.2023.105435
GHB distributes into a small volume of distribution (0.49 ± 0.09 L/kg), indicating limited tissue accumulationpartially supported
Vd 0.49±0.9 L/kg. j.yrtph.2023.105435
Elimination half-life is 20–60 minutes, with some sources reporting 30–50 minutes.supported
half-life 30-50 min. 1570159x13666141210215423
Elimination half-life is 20–60 minutes, with some sources reporting 30–50 minutes.supported
half-life 20-60 min. j.yrtph.2023.105435
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
GHB is a substrate for monocarboxylate transporters (MCT/SLC16A family) in the intestine, kidney, and brain; renal clearance is dose-dependent due to saturable MCT-mediated tubular reabsorptionsupported
GHB is substrate for MCT transporters. Renal clearance is dose-dependent (MCT saturation). s12248-008-9035-6
Only 1–5% of the administered dose is recoverable unchanged in urine.supported
1-5% dose recoverable in urine. 1570159x13666141210215423
Detection windows are short — approximately 6 hours in blood and 10 hours in urine — which complicates forensic investigation of drug-facilitated sexual assaultsupported
Detection windows 6h blood, 10h urine. j.yrtph.2023.105435
Endogenous urinary GHB baseline in women averages 0.84 mg/L; a threshold of 10 mg/L is used as a discriminant for exogenous GHB exposure in DFSA cases.supported
Endogenous GHB in 1126 women: mean 0.84 mg/L. Supports 10 mg/L discriminant limit for GHB/GBL administration. pmid:21073808
summary12 · 7 ok
Gamma-butyrolactone (GBL, oxolan-2-one) is a cyclic lactone prodrug that undergoes near-instantaneous hydrolysis to gamma-hydroxybutyric acid (ghb) via blood lactonases (conversion half-life ~1 minute)supported
GBL/BD rapidly converted to GHB (t1/2 ~1 min). 1570159x13666141210215423
Claim in summary — inconclusiveinconclusiveworking →
GBL remains a primary chemsex substance in MSM communities across Europe and Australia.supported
Reviews GHB/GBL/1,4-BD, mephedrone, methamphetamine and other chemsex drugs. Covers mechanisms, toxicity, patterns of use, and health consequences including STI transmission risks. 1570159x15666161117151148
GBL's pharmacological effects are entirely GABA-B-mediated — all CNS activity is abolished in GABA-B(1)-knockout micesupported
GABA-B(1)-/- mice retain GHB-specific binding sites but lose GHB pharmacological effects (hypolocomotion, hypothermia, dopamine synthesis changes, EEG delta waves). All studied GHB effects are GABA-B dependent. pmid:14656321
GBL's pharmacological effects are entirely GABA-B-mediated — all CNS activity is abolished in GABA-B(1)-knockout micesupported
GBL and baclofen both require GABA-B receptors for their sedative effects (absent in GABA-B knockout mice). GBL effects fully GABA-B mediated. jneurosci.3145-10.2010
Claim in summary — inconclusiveinconclusiveworking →
A recently identified high-affinity target — CaMKII-alpha (Kd in the nM range) — suggests GHB integrates inhibitory and excitatory signalingsupported
Comprehensive IUPHAR review identifying CaM-dependent protein kinase II alpha subunit as high-affinity GHB target. GHB weak agonist at GABA-B; high-affinity binding at CaMKII-alpha subunit. j.pharmr.2025.100064
Acute toxicity is high relative to the recreational dose range: estimated lethal dose is ~60 mg/kg in humans, and death occurs primarily via respiratory depression and aspiration during unconsciousness. Physical dependence develops rapidly — faster than alcohol or benzodiazepines — and withdrawal is medically serious, featuring hallucinations (63%), tremor (67%), tachycardia (63%), and seizures (7%) in a systematic review of 57 episodespartially supported
Lethal dose ~60 mg/kg. ~100 mg/L euphoria; 500 mg/L may cause death. j.yrtph.2023.105435
Acute toxicity is high relative to the recreational dose range: estimated lethal dose is ~60 mg/kg in humans, and death occurs primarily via respiratory depression and aspiration during unconsciousness. Physical dependence develops rapidly — faster than alcohol or benzodiazepines — and withdrawal is medically serious, featuring hallucinations (63%), tremor (67%), tachycardia (63%), and seizures (7%) in a systematic review of 57 episodespartially supported
Case report: 25yo man found unconscious, presented in asystole after isolated GBL ingestion. Pulmonary aspiration postmortem. First confirmed isolated GBL fatality in UK. jrsm.2009.090283
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
history11 · 8 ok
Through the 1990s, both compounds gained widespread popularity as club drugs under names such as "liquid ecstasy" and "G," and became increasingly implicated in drug-facilitated sexual assault (DFSA) cases and fatalities — particularly in combination with alcohol.supported
Reviews chemistry and pharmacology of GHB, GBL, and 1,4-BD and their use in DFSA. Discusses Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000. pmid:26242455
Following the first confirmed UK GBL fatality — a 25-year-old male who died of asystole after isolated GBL ingestion — and subsequent ACMD advice, GBL was reclassified as a Class B substance under the Misuse of Drugs Act 1971, effective December 2009partially supported
Case report: 25yo man found unconscious, presented in asystole after isolated GBL ingestion. First confirmed isolated GBL fatality in UK. jrsm.2009.090283
Case reports document ongoing fatalities and severe withdrawal presentations, including rhabdomyolysis with dialysis-dependent renal failure and prolonged psychiatric disturbance.supported
GBL withdrawal delirium complicated by rhabdomyolysis and dialysis-dependent renal failure. s-0029-1220252
Case reports document ongoing fatalities and severe withdrawal presentations, including rhabdomyolysis with dialysis-dependent renal failure and prolonged psychiatric disturbance.supported
29yo GBL user with bizarre psychiatric presentation, needed extensive investigations. Dramatic recovery day 11. pmid:21894099
Its pharmacological significance derives entirely from its relationship to ghb: after oral ingestion, GBL is hydrolyzed to GHB within approximately one minute by blood lactonase enzymes.supported
GBL/BD rapidly converted to GHB (t1/2 ~1 min). 1570159x13666141210215423
Claim in history — inconclusiveinconclusiveworking →
During the 1980s, GHB was promoted as an over-the-counter dietary supplement and bodybuilding aid based on its capacity to stimulate growth hormone secretionsupported
Bedtime GHB (2.5-3.5g) doubled GH secretion with increased amplitude/duration of first GH pulse. jci119587
Claim in history — inconclusiveinconclusiveworking →
Claim in history — not_supportednot supportedworking →
GBL continues to circulate globally as both a legal industrial chemical and an illicit recreational substance, and it remains a primary chemsex drug in MSM (men who have sex with men) communities across Europe and Australiasupported
Reviews GHB/GBL/1,4-BD, mephedrone, methamphetamine and other chemsex drugs. Covers mechanisms, toxicity, patterns of use. 1570159x15666161117151148
GBL continues to circulate globally as both a legal industrial chemical and an illicit recreational substance, and it remains a primary chemsex drug in MSM (men who have sex with men) communities across Europe and Australiasupported
Chemsex study in MSM/HIV+ across 4 European countries. GHB/GBL explicitly identified as chemsex drugs. hiv.13160
neuroscience10 · 6 ok
Chronic GBL/GHB exposure drives neuroadaptations across at least six neurotransmitter systems: GABAergic (downregulation of both GABA-B and specific gaba-a-receptor subtypes), glutamatergic (upregulation, contributing to hyperexcitability upon withdrawal), dopaminergic, serotonergic, noradrenergic, and cholinergicsupported
Chronic GHB affects GABA, glutamate, dopamine, serotonin, norepinephrine, cholinergic systems. 000443173
Upon cessation, the combined gaba downregulation and glutamate upregulation produces a hyperexcitable state manifesting as tremor, tachycardia, hypertension, hallucinations, and seizures — pharmacologically analogous to alcohol withdrawal but complicated by the additional GABA-B and extrasynaptic GABA-A (alpha-4/delta) components that are not addressed by benzodiazepines.supported
Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. Barbiturates suggested as alternative. 01.pra.0000452567.84825.07
Claim in neuroscience — inconclusiveinconclusiveworking →
Why do animal models fail to replicate GBL dependence? Animal studies consistently fail to produce the physical-dependence and withdrawal syndrome observed in human chronic userssupported
Notes GBL not associated with dependence in animal studies but human case reports show high dependence potential. pmid:21894099
At pharmacological doses, GHB produces characteristic high-amplitude delta-wave (0.5–4 Hz) activity on EEG, distinct from both physiological non-REM sleep and baclofen-induced sedationsupported
GBL induces drug-distinct-from-physiological-sleep state, not associated with subsequent hypersomnia unlike baclofen. jneurosci.3145-10.2010
This delta induction is entirely GABA-B-dependent (abolished in knockout mice) and is associated with the subjective experience of deep sedation and unconsciousness at higher dosessupported
GABA-B(1)-/- mice lose GHB pharmacological effects (EEG delta waves). All studied GHB effects are GABA-B dependent. pmid:14656321
Claim in neuroscience — inconclusiveinconclusiveworking →
The recently identified CaMKII-alpha target adds complexitysupported
Comprehensive IUPHAR review identifying CaM-dependent protein kinase II alpha subunit as high-affinity GHB target. j.pharmr.2025.100064
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
clinical-evidence8 · 7 ok
Dargan et al. (2009) reported the first confirmed UK GBL fatality: a 25-year-old male with 282 mg/L GBL in femoral blood, cause of death aspiration secondary to comasupported
Case report: 25yo man found unconscious. Femoral blood GBL: 282 mg/L. Pulmonary aspiration postmortem. First confirmed isolated GBL fatality in UK. jrsm.2009.090283
Lenz et al. (2008) described two GBL fatalities (one suicide, one accidental) with full organ distribution of GHB by GC/MS analysis of postmortem specimenssupported
Two GBL fatalities and one nonfatal intoxication. GHB quantified by GC/MS. Cause of death: GHB intoxication; one suicide, one accidental. ftd.0b013e3181898c2e
Supady et al. (2009) reported GBL withdrawal complicated by rhabdomyolysis and dialysis-dependent acute renal failure in a 24-year-old with a dosing pattern of 2 mL every 30 minutessupported
24yo man with known GBL abuse (2 mL every 30 min). GBL withdrawal delirium complicated by rhabdomyolysis and dialysis-dependent renal failure. s-0029-1220252
Lingford-Hughes et al. (2016) published the protocol for a feasibility randomized controlled trial (NCT02342366) evaluating baclofen as an adjunct for GHB/GBL withdrawal managementsupported
GABA-B agonist baclofen has shown promise as adjunct. Benzodiazepines are currently prescribed for detoxification. pmid:27677382
Claim in clinical-evidence — not_supportednot supportedworking →
GHB's capacity to enhance oxytocin release provides a plausible mechanistic basis for the empathogenic and prosocial effects reported by recreational GBL users.supported
Chronic GHB affects... Also neurosteroidogenesis and oxytocin. 000443173
Van Cauter et al. (1997) demonstrated that GHB simultaneously stimulates slow-wave sleep and growth hormone secretion in normal young men in a randomized controlled trial, confirming the mechanistic basis for GBL/GHB's historical use as a bodybuilding supplement.supported
Bedtime GHB (2.5-3.5g) doubled GH secretion with increased amplitude/duration of first GH pulse. Correlated with increased sleep stage IV. jci119587
Galicia et al. (2019) demonstrated that ethanol co-ingestion significantly worsens clinical outcomes in GHB/GBL intoxication presentations to European emergency departmentssupported
Ethanol coingestion with GHB/GBL increases sedative effects and worsens clinical outcomes at ED presentations. j.toxlet.2019.07.001
pharmacokinetic-detail8 · 4 ok
Morse and Morris (2013) demonstrated that intravenous L-lactate, a competitive MCT substrate, could accelerate GHB/GBL clearance by inhibiting tubular reabsorption, offering a potential overdose treatment strategy — though this approach is not yet standard of care.supported
IV L-lactate (MCT inhibitor) increases GHB renal and oral clearance, reduces respiratory depression, reduces mortality in high-dose GBL. Potential treatment strategy for oral GHB/GBL overdose. jpet.112.202796
The hydrolysis of GBL to ghb occurs via lactonase activity in blood and tissues with a conversion half-life of approximately one minutesupported
GBL/BD rapidly converted to GHB (t1/2 ~1 min). 1570159x13666141210215423
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
The small volume of distribution (0.49 L/kg) indicates that GHB does not accumulate extensively in peripheral tissuessupported
Vd 0.49±0.9 L/kg. j.yrtph.2023.105435
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Towiwat et al. (2013) found that chronic equimolar GHB produced greater tolerance than chronic GBL in mice, attributed to rate-limiting metabolic conversion from GBL to GHB — the slower, sustained GHB release from GBL may produce different receptor occupancy kineticssupported
Chronic GHB shows greater tolerance development than GBL or 1,4-BD. Rate of metabolic conversion responsible for tolerance differences. j.fct.2012.10.009
comparative-pharmacology5 · 3 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
This mechanistic divergence explains why benzodiazepines provide incomplete coverage during GBL withdrawal and why the GBL withdrawal syndrome, while resembling alcohol withdrawal, can be more refractory to standard sedative-hypnotic management.supported
Resistance to benzodiazepines noted. Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. 01.pra.0000452567.84825.07
Towiwat et al. (2013) reported less tolerance development with chronic GBL than with equimolar chronic GHB in a mouse catalepsy modelsupported
Equimolar doses of GHB, 1,4-BD, and GBL all produce catalepsy. Chronic GHB shows greater tolerance development than GBL or 1,4-BD. j.fct.2012.10.009
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Vienne et al. (2010) demonstrated that GBL and baclofen produce distinct EEG signatures despite shared GABA-B agonism, with GBL-induced patterns differing from both baclofen-induced patterns and physiological sleepsupported
GBL induces drug-distinct-from-physiological-sleep state, not associated with subsequent hypersomnia unlike baclofen. jneurosci.3145-10.2010
receptor-pharmacology4 · 3 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
The identification of CaMKII-alpha as the high-affinity GHB target represents a major advancesupported
Comprehensive IUPHAR review identifying CaM-dependent protein kinase II alpha subunit as high-affinity GHB target. j.pharmr.2025.100064
These receptor subtypes mediate tonic (extrasynaptic) inhibition and are the primary targets of neurosteroids and barbiturates, but are insensitive to classical benzodiazepinessupported
Resistance to benzodiazepines noted. Reviews difference between BZD (GABA-A) and GBL (GABA-B + extrasynaptic GABA-A) mechanisms. Barbiturates suggested as alternative. 01.pra.0000452567.84825.07
Kamal et al. (2016) documented changes across glutamatergic, dopaminergic, serotonergic, noradrenergic, and cholinergic neurotransmission, as well as alterations in neurosteroidogenesis and oxytocin releasesupported
Chronic GHB affects GABA, glutamate, dopamine, serotonin, norepinephrine, cholinergic systems. Also neurosteroidogenesis and oxytocin. 000443173